Lcnb Corp Has $338,000 Position in Pfizer Inc. (NYSE:PFE)

Key Points

• Lcnb Corp decreased its holdings in Pfizer Inc. by 66.6%, owning 13,343 shares worth $338,000 after selling 26,557 shares during the first quarter.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, exceeding estimates of $0.58, with revenue increasing by 10.3% year-over-year to $14.65 billion.
• The company declared a quarterly dividend of $0.43, resulting in an annualized dividend yield of 7.0%, although its payout ratio stands at a high 91.49%.

Lcnb Corp lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 66.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,343 shares of the biopharmaceutical company's stock after selling 26,557 shares during the quarter. Lcnb Corp's holdings in Pfizer were worth $338,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Northern Trust Corp boosted its holdings in shares of Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after buying an additional 4,167,222 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after buying an additional 1,333,740 shares during the period. Deutsche Bank AG boosted its holdings in shares of Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after buying an additional 1,846,436 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

PFE stock opened at $24.57 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a market cap of $139.69 billion, a P/E ratio of 13.07, a P/E/G ratio of 0.87 and a beta of 0.52. The company's 50-day moving average price is $24.44 and its two-hundred day moving average price is $24.50.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm earned $0.60 EPS. The business's quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday. Wolfe Research upped their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. BMO Capital Markets reduced their target price on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Finally, Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.